Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMER4-i
- Development stage
- Preclinical
- Lead developer
- Crossignal Therapeutics
- Modality
- Small Molecules
01
Overview
TMER4-i is a small-molecule inhibitor currently in the hit-to-lead stage of development by Crossignal Therapeutics. It is part of the company's Tumor Microenvironment Reprogramming (TMER) series of assets, which are designed to modulate the immune and metabolic landscape of the tumor environment to overcome resistance and enhance anti-tumor activity. While the specific molecular target of TMER4-i remains undisclosed, the program is being developed for the treatment of various solid tumors, potentially as a monotherapy or in combination with other immune-oncology agents such as PD-1/PD-L1 blockers.
- Other names
- TMER4 vtRNA-SL1TMER-4 vtRNA-SL1TMER 4 vtRNA-SL1
Beyond the preview
Go deeper on TMER4-i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMER4-i.